Business Context and Reporting Period
This Form 6-K filing by Legend Biotech Corporation, dated February 6, 2026, reports a corporate governance update. The filing announces the appointment of Gareth Kung to the Board of Directors, effective February 2, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation.
Material Changes
- Board Appointment: Gareth Kung was appointed as a Class II director, with a term extending until the 2028 annual general meeting.
- Committee Leadership: Mr. Kung replaced Tomas Heyman as the chair of the Audit Committee.
- Compensation Structure:
- Equity: Grant of restricted share units (RSUs) valued at $270,000, vesting over three years (one-third on the first anniversary, followed by quarterly vesting).
- Cash Retainers: $75,000 annually for Board service and $25,000 annually for serving as Audit Committee chair.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of material risks and contingencies. It confirms there are no undisclosed related-party transactions or special arrangements regarding Mr. Kung's appointment.
Key Facts for Investor Verification
- Verify the closing price of Legend Biotech's ADS on February 2, 2026, to calculate the exact number of RSUs granted to Mr. Kung.
- Confirm the departure of Tomas Heyman from the Audit Committee chair role.
- Review Mr. Kung's background in semiconductor and finance sectors to assess his fit for the Audit Committee.
- Note that this filing does not contain financial performance data for the period.